A Phase 3 interventional study of Trastuzumab deruxtecan and Capecitabine in Advanced or Metastatic Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 293 sites in 28 countries. Open to participants aged 18 Years to 105 Years. Per ClinicalTrials.gov, last updated 2026-03-04.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.
Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 4th largest by enrollment, is one of 9 that started in 2020, is one of 12 in phase 3, reaches primary completion later than 2 of the 44 other live ones, and was the 12th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
SOLTI Breast Cancer Research Group · Sites in France, Germany, Spain
Ages 18+
Kristina A. Fanucci · Sites in United States
Ages 18+
Institut Claudius Regaud · Sites in France
Ages 18+
By country, each count listing its studies:
trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 105 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab deruxtecan is the treatment under test here. Read study by study →
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 37 · Phase 3 12 · Phase 4 2
First in 2017; this study’s year is marked. 9 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 866 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 139 across the 58 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 58 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 16th largest by enrollment of the 125 interventional ones that give a count, is one of 11 that started in 2020, is one of 46 in phase 3, reaches primary completion later than 6 of the 49 other live ones, and was the 130th registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
13 of the studies testing trastuzumab deruxtecan in Breast Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT05950945Phase 3Daiichi SankyoTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | 2027-10-01 |
| NCT06048718MedSIRT-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases | 2026-11 |
| NCT04553770Jonsson Comprehensive Cancer CenterTrastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | 2026-12-31 |
| NCT06486883MedSIRSafety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype | 2027-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.
Eligible patients will be those patients who have had disease progression on at least 2 previous lines of endocrine therapies given for the treatment of metastatic disease or disease progression within 6 months of starting first line treatment for metastatic disease with an endocrine therapy combined with a CDK4/6 inhibitor. All patients must have historically confirmed HR positive (either estrogen receptor and/or progesterone receptor positive), HER2-low (defined as IHC2+/ISH- and IHC 1+) or HER2 IHC >0 \<1+ expression, as determined by central laboratory testing results, advanced or metastatic breast cancer.
The study aims to evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy. This study aims to see if trastuzumab deruxtecan allows patients to live longer without the cancer getting worse, or simply to live longer, compared to patients receiving standard of care chemotherapy. This study is also looking to see how the treatment and the cancer affects patients' quality of life.
Key Inclusion Criteria:
documented breast cancer that:
Must have either:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Trastuzumab deruxtecan (T-DXd; DS-8201a) arm
Drug: Trastuzumab deruxtecan
Investigator's choice standard of care chemotherapy (capecitabine, paclitaxel, nab-paclitaxel) arm
Drug: Capecitabine · Drug: Paclitaxel · Drug: Nab-Paclitaxel
Trastuzumab deruxtecan by intravenous infusion
Also known as: DS-8201a; T-DXd
Investigator's choice standard of care single agent chemotherapy; capecitabine tablets will be given orally.
Investigator's choice standard of care single agent chemotherapy; paclitaxel by intravenous infusion.
Investigator's choice standard of care single agent chemotherapy; nab-paclitaxel by intravenous infusion
Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population
PFS per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) assessed by BICR was defined as the time from the date of randomization until the date of PD, as defined or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy prior to progression. PD was defined as at least a 20% increase in the sum of diameters of target lesions (TLs), taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 millimeter (mm) from nadir. Median PFS was calculated using Kaplan-Meier method and its confidence interval (CI) using Brookmeyer-Crowley method.
Time frame: Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Overall Survival (OS) in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population
OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy. Median OS was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.
Time frame: From date of randomization until death due to any cause, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Progression-Free Survival Assessed by Blinded Independent Central Review in the Intent-to-Treat, Human Epidermal Growth Factor Receptor 2 Immunohistochemistry (IHC) >0 <1+ and Human Epidermal Growth Factor Receptor 2-low Population
PFS per RECIST 1.1 assessed by BICR was defined as the time from the date of randomization until the date of PD, as defined or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy prior to progression. PD was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 mm from nadir. Median PFS was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.
Time frame: Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Overall Survival (OS) in the Intent-to-Treat Population
OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy. Median OS was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.
Time frame: From date of randomization until death due to any cause, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Progression-Free Survival Assessed by Investigator in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population
PFS per RECIST 1.1 assessed by Investigator was defined as the time from the date of randomization until the date of PD, as defined or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy prior to progression. PD was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 mm from nadir. Median PFS was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.
Time frame: Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Objective Response Rate (ORR) Assessed by Blinded Independent Central Review and Investigator in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population
ORR per RECIST 1.1 assessed by BICR and Investigator was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR). CR was defined as disappearance of all TLs since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.
Time frame: Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Duration of Response (DOR) Assessed by Blinded Independent Central Review and Investigator in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population
DOR per RECIST v1.1 was defined as the time from the date of first documented response until date of documented progression or death in the absence of PD. PD was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 mm from nadir. Median DOR was calculated using Kaplan-Meier method.
Time frame: Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Objective Response Rate Assessed by Blinded Independent Central Review and Investigator in the Intent-to-Treat and Human Epidermal Growth Factor Receptor 2 Immunohistochemistry >0 <1+ Population
ORR per RECIST 1.1 assessed by BICR and Investigator was defined as the percentage of participants with at least 1 visit response of CR or PR. CR was defined as disappearance of all TLs since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.
Time frame: Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Duration of Response Assessed by Blinded Independent Central Review and Investigator in the Intent-to-Treat Population
DOR per RECIST v1.1 was defined as the time from the date of first documented response until date of documented progression or death in the absence of PD. PD was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 mm from nadir. Median DOR was calculated using Kaplan-Meier method.
Time frame: Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Time From Randomization to Second Progression or Death (PFS2) in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low and Intent-to-Treat Population
PFS2 was defined as time from randomization to second progression (the earliest of the progression event subsequent to first subsequent therapy) or death; second progression was defined according to local standard clinical practice and might involve any of the following: objective radiological imaging, symptomatic progression, or death. Median PFS2 was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.
Time frame: Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. A serious adverse event (SAE) was an AE occurring during any study phase, that fulfilled 1 or more of following criteria: resulted in death, was immediately life-threatening, required in-participant hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was congenital abnormality or birth defect, and was an important medical event that jeopardized participant or required medical treatment to prevent 1 of outcomes listed above. TEAE was any AE that occurred, having been absent before the first dose of study drug, or had worsened in severity or seriousness after initiation of the study drug until the 40-day (+7 days) safety follow-up visit.
Time frame: From first dose of study drug (Day 1) up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Serum Concentration of Trastuzumab Deruxtecan (T-DXd), Total Anti-Human Epidermal Growth Factor Receptor 2 Antibody and MAAA-1181a
Blood samples were collected at indicated time points to determine the concentration of T-DXd, total anti-HER2 antibody and MAAA-1181a in serum.
Time frame: Pre-dose on Day 1 of Cycles 1, 2, 4, 6 and 8; 15 minutes post-dose on Day 1 of Cycles 1, 2 and 4; and 5 hours post-dose on Day 1 of Cycle 1 (each cycle is 21 days)
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Scale Score at Week 91
EORTC QLQ-C30 is a 30-item self-administered questionnaire grouped into 5 multi-item functional scales(physical,role,emotional,cognitive and social),3 multiitem symptom scales(fatigue,pain and nausea/vomiting),2-item global QoL scale,5 single items assessing additional symptoms reported by cancer participants(dyspnea,loss of appetite,insomnia,constipation and diarrhea). All but 2 questions have 4-point scales:1:not at all,2:a little,3:quite a bit,4:very much.2 questions concerning global health status and QoL have 7-point scales with responses ranging from 1:very poor to 7:excellent;higher score:better level of functioning/greater degree of symptoms.For each of 15 scales,final scores were averaged from scores of component items,transformed,range: 0 to 100;higher scores:better functioning,better health related (HR)QoL,or greater level of symptoms(higher scores:opposite interpretations for functioning/QoL and symptoms/problems).Baseline:last observed measurement prior to randomization.
Time frame: Baseline (Day 1) and Week 91
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Breast Module 45 (BR45) Scale Score at Week 58
EORTC QLQ-BR45 is an updated version of the BR23. Self-administered instrument includes original 23-items yielding 5 multi-item scores (body image, sexual functioning, arm symptoms, breast symptoms, and systemic therapy side effects). Additional 22 items yield 4 additional multi-item scales (breast satisfaction, endocrine therapy symptoms, skin mucosis symptoms, and endocrine sexual symptoms). Single items assess sexual enjoyment, future perspective and being upset by hair loss. Items are scored on a 4-point verbal rating scale: 1: not at all, 2: a little, 3: quite a bit, and 4: very much; higher score: better level of functioning or greater degree of symptoms. Scores of these scales were averaged from scores of component items, transformed, and ranged from 0 to 100; higher scores for functioning scales or items indicate better functioning, whereas higher scores for symptom scales or items represent a higher level of symptoms. Baseline:last observed measurement prior to randomization.
Time frame: Baseline (Day 1) and Week 58
Time to Deterioration in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Scale Score
Time to deterioration was defined as the time from randomization until the date of the first clinically meaningful deterioration that was confirmed at next available assessment, at least 14 days apart, regardless of whether the participant withdrew from study treatment or receives another anti-cancer therapy prior to deterioration.
Time frame: From randomization until date of first symptom deterioration that is confirmed, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Number of Participants With Anti-Drug Antibodies (ADAs) Against Trastuzumab Deruxtecan
Blood samples were collected at indicated timepoints to determine ADA. Treatment-induced ADA was defined as ADA positive post-baseline and not detected at baseline (negative or missing). Treatment-boosted ADA was defined as a baseline positive ADA titer that was boosted to a 4-fold or higher-level following drug administration.
Time frame: From Day 1 up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Time to First Subsequent Treatment or Death (TFST) in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low and Intent-to-Treat Population
TFST was defined as time from randomization to the start date of the first subsequent anti-cancer therapy after discontinuation of randomized treatment or death due to any cause.
Time frame: From Day 1 up to 64 months
Time to Second Subsequent Treatment or Death (TSST) in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low and Intent-to-Treat Population
TSST was defined as time from randomization to the start date of the second subsequent anti-cancer therapy after discontinuation of randomized treatment or death due to any cause.
Time frame: From Day 1 up to 64 months
This Phase III, multi-center, open-label study was conducted in participants with human epidermal growth factor receptor 2 (HER2)-low, hormone receptor-positive (HR+) breast cancer at 273 sites in 28 countries. Results are presented based on primary completion date (PCD) of up to 18 March 2024.
| Milestone | T-DXd | Chemotherapy |
|---|---|---|
| Started | 436 | 430 |
| Randomized and received treatment | 434 | 417 |
| Completed | 0 | 0 |
| Not completed | 436 | 430 |
| Withdrew: Death | 160 | 166 |
| Withdrew: Withdrawal by subject | 10 | 40 |
| Withdrew: Other | 1 | 1 |
| Withdrew: Ongoing at the time of pcd | 265 | 223 |
PFS per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) assessed by BICR was defined as the time from the date of randomization until the date of PD, as defined or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy prior to progression. PD was defined as at least a 20% increase in the sum of diameters of target lesions (TLs), taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 millimeter (mm) from nadir. Median PFS was calculated using Kaplan-Meier method and its confidence interval (CI) using Brookmeyer-Crowley method.
| months | T-DXd | Chemotherapy |
|---|---|---|
| Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population | 13.2 (11.4 to 15.2) | 8.1 (7.0 to 9.0) |
OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy. Median OS was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.
| months | T-DXd | Chemotherapy |
|---|---|---|
| Overall Survival (OS) in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population | 28.9 (25.7 to 33.7) | 27.1 (23.5 to 29.9) |
PFS per RECIST 1.1 assessed by BICR was defined as the time from the date of randomization until the date of PD, as defined or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy prior to progression. PD was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 mm from nadir. Median PFS was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.
| months | T-DXd | Chemotherapy |
|---|---|---|
| ITT Population | 13.2 (12.0 to 15.2) | 8.1 (7.0 to 9.0) |
| HER2 IHC >0 <1+ Population | 13.2 (9.8 to 17.3) | 8.3 (5.8 to 15.2) |
| HER2-low Population | 12.8 (11.1 to 13.2) | 7.0 (6.4 to 7.5) |
OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy. Median OS was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.
| months | T-DXd | Chemotherapy |
|---|---|---|
| Overall Survival (OS) in the Intent-to-Treat Population | 28.9 (26.4 to 32.7) | 27.4 (23.9 to 29.9) |
PFS per RECIST 1.1 assessed by Investigator was defined as the time from the date of randomization until the date of PD, as defined or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy prior to progression. PD was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 mm from nadir. Median PFS was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.
| months | T-DXd | Chemotherapy |
|---|---|---|
| Progression-Free Survival Assessed by Investigator in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population | 12.8 (11.1 to 13.2) | 7.0 (6.4 to 7.5) |
ORR per RECIST 1.1 assessed by BICR and Investigator was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR). CR was defined as disappearance of all TLs since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.
| percentage of participants | T-DXd | Chemotherapy |
|---|---|---|
| BICR Assessment | 60.4 | 37.9 |
| Investigator Assessment | 60.4 | 40.4 |
DOR per RECIST v1.1 was defined as the time from the date of first documented response until date of documented progression or death in the absence of PD. PD was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 mm from nadir. Median DOR was calculated using Kaplan-Meier method.
| months | T-DXd | Chemotherapy |
|---|---|---|
| BICR Assessment | 13.6 (6.2 to 24.9) | 7.3 (4.2 to 15.2) |
| Investigator Assessment | 12.0 (6.6 to 20.0) | 6.9 (3.1 to 11.1) |
ORR per RECIST 1.1 assessed by BICR and Investigator was defined as the percentage of participants with at least 1 visit response of CR or PR. CR was defined as disappearance of all TLs since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.
| percentage of participants | T-DXd | Chemotherapy |
|---|---|---|
| BICR Assessment: ITT Population | 61.5 | 36.7 |
| Investigator Assessment: ITT Population | 61.5 | 38.8 |
| BICR Assessment: HER2 IHC >0 <1+ Population | 67.1 | 31.6 |
| Investigator Assessment: HER2 IHC >0 <1+ Population | 65.8 | 31.6 |
DOR per RECIST v1.1 was defined as the time from the date of first documented response until date of documented progression or death in the absence of PD. PD was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 mm from nadir. Median DOR was calculated using Kaplan-Meier method.
| months | T-DXd | Chemotherapy |
|---|---|---|
| BICR Assessment | 13.7 (6.5 to 24.9) | 7.3 (4.2 to 15.9) |
| Investigator Assessment | 12.1 (6.8 to 20.0) | 6.9 (3.0 to 12.5) |
PFS2 was defined as time from randomization to second progression (the earliest of the progression event subsequent to first subsequent therapy) or death; second progression was defined according to local standard clinical practice and might involve any of the following: objective radiological imaging, symptomatic progression, or death. Median PFS2 was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.
| months | T-DXd | Chemotherapy |
|---|---|---|
| HER2-low Population | 20.0 (18.9 to 23.8) | 14.5 (12.9 to 15.5) |
| ITT Population | 20.3 (18.9 to 23.8) | 14.7 (13.5 to 15.9) |
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. A serious adverse event (SAE) was an AE occurring during any study phase, that fulfilled 1 or more of following criteria: resulted in death, was immediately life-threatening, required in-participant hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was congenital abnormality or birth defect, and was an important medical event that jeopardized participant or required medical treatment to prevent 1 of outcomes listed above. TEAE was any AE that occurred, having been absent before the first dose of study drug, or had worsened in severity or seriousness after initiation of the study drug until the 40-day (+7 days) safety follow-up visit.
| Participants | T-DXd | Chemotherapy |
|---|---|---|
| TEAEs | 429 | 397 |
| TESAEs | 88 | 67 |
Blood samples were collected at indicated time points to determine the concentration of T-DXd, total anti-HER2 antibody and MAAA-1181a in serum.
| micrograms per milliliter (mcg/mL) | T-DXd |
|---|---|
| T-DXd: Day 1: pre-dose, Cycle 1 | NA ± NA |
| T-DXd: Day 1: pre-dose, Cycle 2 | 4.35225 ± 8.958729 |
| T-DXd: Day 1: pre-dose, Cycle 4 | 8.21037 ± 9.464435 |
| T-DXd: Day 1: pre-dose, Cycle 6 | 8.65950 ± 4.753592 |
| T-DXd: Day 1: pre-dose, Cycle 8 | 11.31496 ± 22.894112 |
| T-DXd: Day 1: 15 minutes post-dose, Cycle 1 | 135.90160 ± 102.989325 |
| T-DXd: Day 1: 15 minutes post-dose, Cycle 2 | 136.74872 ± 108.860006 |
| T-DXd: Day 1: 15 minutes post-dose, Cycle 4 | 124.60481 ± 39.812165 |
| T-DXd: Day 1: 5 hours post-dose, Cycle 1 | 123.82288 ± 30.513998 |
| Total anti-HER2 antibody: Day 1: pre-dose, Cycle 1 | NA ± NA |
| Total anti-HER2 antibody: Day 1: pre-dose, Cycle 2 | 5.75841 ± 11.351915 |
| Total anti-HER2 antibody: Day 1: pre-dose, Cycle 4 | 12.00513 ± 11.087226 |
| Total anti-HER2 antibody: Day 1: pre-dose, Cycle 6 | 13.97891 ± 8.720790 |
| Total anti-HER2 antibody: Day 1: pre-dose, Cycle 8 | 17.47641 ± 27.144299 |
| Total anti-HER2 antibody: Day 1: 15 minutes post-dose, Cycle 1 | 141.27586 ± 114.137606 |
| Total anti-HER2 antibody: Day 1: 15 minutes post-dose, Cycle 2 | 146.17993 ± 134.780719 |
| Total anti-HER2 antibody: Day 1: 15 minutes post-dose, Cycle 4 | 131.06830 ± 44.228380 |
| Total anti-HER2 antibody: Day 1: 5 hours post-dose, Cycle 1 | 119.64619 ± 26.591288 |
| MAAA-1181a: Day 1: pre-dose, Cycle 1 | NA ± NA |
| MAAA-1181a: Day 1: pre-dose, Cycle 2 | 0.261850 ± 0.2096642 |
| MAAA-1181a: Day 1: pre-dose, Cycle 4 | 0.401004 ± 0.2825761 |
| MAAA-1181a: Day 1: pre-dose, Cycle 6 | 0.446237 ± 0.2957478 |
| MAAA-1181a: Day 1: pre-dose, Cycle 8 | 0.432894 ± 0.2819292 |
| MAAA-1181a: Day 1: 15 minutes post-dose, Cycle 1 | 6.014366 ± 3.1859583 |
| MAAA-1181a: Day 1: 15 minutes post-dose, Cycle 2 | 2.985606 ± 1.9276120 |
| MAAA-1181a: Day 1: 15 minutes post-dose, Cycle 4 | 2.411409 ± 1.5862547 |
| MAAA-1181a: Day 1: 5 hours post-dose, Cycle 1 | 13.917874 ± 6.5178612 |
EORTC QLQ-C30 is a 30-item self-administered questionnaire grouped into 5 multi-item functional scales(physical,role,emotional,cognitive and social),3 multiitem symptom scales(fatigue,pain and nausea/vomiting),2-item global QoL scale,5 single items assessing additional symptoms reported by cancer participants(dyspnea,loss of appetite,insomnia,constipation and diarrhea). All but 2 questions have 4-point scales:1:not at all,2:a little,3:quite a bit,4:very much.2 questions concerning global health status and QoL have 7-point scales with responses ranging from 1:very poor to 7:excellent;higher score:better level of functioning/greater degree of symptoms.For each of 15 scales,final scores were averaged from scores of component items,transformed,range: 0 to 100;higher scores:better functioning,better health related (HR)QoL,or greater level of symptoms(higher scores:opposite interpretations for functioning/QoL and symptoms/problems).Baseline:last observed measurement prior to randomization.
| score on a scale | T-DXd | Chemotherapy |
|---|---|---|
| Physical Functioning | -7.88 ± 17.389 | -4.85 ± 13.520 |
| Role Functioning | -14.77 ± 21.631 | -12.12 ± 26.318 |
| Emotional Functioning | -6.06 ± 25.440 | 1.52 ± 22.218 |
| Cognitive Functioning | -8.71 ± 22.872 | -6.82 ± 19.009 |
| Social Functioning | -10.98 ± 23.000 | -7.58 ± 21.656 |
| Fatigue | 11.87 ± 24.367 | 8.59 ± 18.444 |
| Pain | -1.89 ± 21.025 | -0.76 ± 24.922 |
| Nausea/Vomiting | 9.85 ± 19.128 | -0.76 ± 12.037 |
| Global Health Status/QoL | -7.77 ± 23.529 | -10.61 ± 22.150 |
| Dyspnea | 6.06 ± 23.041 | 1.52 ± 21.767 |
| Loss of Appetite | 12.88 ± 30.682 | 6.06 ± 19.616 |
| Insomnia | 6.06 ± 26.190 | -15.15 ± 24.618 |
| Constipation | 11.36 ± 30.452 | 1.52 ± 12.503 |
| Diarrhea | 6.82 ± 19.792 | 13.64 ± 28.469 |
EORTC QLQ-BR45 is an updated version of the BR23. Self-administered instrument includes original 23-items yielding 5 multi-item scores (body image, sexual functioning, arm symptoms, breast symptoms, and systemic therapy side effects). Additional 22 items yield 4 additional multi-item scales (breast satisfaction, endocrine therapy symptoms, skin mucosis symptoms, and endocrine sexual symptoms). Single items assess sexual enjoyment, future perspective and being upset by hair loss. Items are scored on a 4-point verbal rating scale: 1: not at all, 2: a little, 3: quite a bit, and 4: very much; higher score: better level of functioning or greater degree of symptoms. Scores of these scales were averaged from scores of component items, transformed, and ranged from 0 to 100; higher scores for functioning scales or items indicate better functioning, whereas higher scores for symptom scales or items represent a higher level of symptoms. Baseline:last observed measurement prior to randomization.
| score on a scale | T-DXd | Chemotherapy |
|---|---|---|
| Body Image | -3.12 ± 23.585 | -5.42 ± 22.349 |
| Sexual Functioning | -2.96 ± 12.708 | 1.46 ± 14.081 |
| Arm Symptoms | -5.30 ± 20.496 | -3.06 ± 18.540 |
| Breast Symptoms | -2.41 ± 17.132 | -2.19 ± 12.631 |
| Systemic Therapy Side Effects | 5.65 ± 15.536 | 3.99 ± 15.536 |
| Breast Satisfaction | 2.65 ± 30.982 | 0.85 ± 31.428 |
| Endocrine Therapy Symptoms | -0.14 ± 11.316 | 0.17 ± 12.458 |
| Skin Mucosis Symptoms | 4.67 ± 14.721 | 12.22 ± 18.232 |
| Endocrine Sexual Symptoms | 3.66 ± 20.831 | 2.00 ± 15.969 |
| Sexual Enjoyment | -3.03 ± 17.979 | 0.00 ± 20.101 |
| Future Perspective | 8.72 ± 32.161 | 11.25 ± 29.022 |
| Being Upset By Hair Loss | 2.47 ± 34.500 | 0.00 ± 40.825 |
Time to deterioration was defined as the time from randomization until the date of the first clinically meaningful deterioration that was confirmed at next available assessment, at least 14 days apart, regardless of whether the participant withdrew from study treatment or receives another anti-cancer therapy prior to deterioration.
| months | T-DXd | Chemotherapy |
|---|---|---|
| Physical Functioning | 18.0 (15.9 to NA) | 9.9 (6.9 to 15.2) |
| Role Functioning | 10.3 (6.9 to 14.6) | 5.5 (4.1 to 6.9) |
| Emotional Functioning | 28.2 (18.6 to NA) | 17.3 (12.4 to NA) |
| Cognitive Functioning | 11.8 (8.3 to 16.6) | 9.9 (7.8 to 13.8) |
| Social Functioning | 11.7 (7.6 to 16.3) | 7.7 (6.2 to 10.4) |
| Fatigue | 4.3 (3.4 to 7.7) | 2.9 (2.2 to 4.2) |
| Pain | 22.0 (17.2 to NA) | 6.3 (4.8 to 9.6) |
| Nausea/Vomiting | 3.5 (2.8 to 5.6) | 13.8 (7.7 to 21.5) |
| Global Health Status/QoL | 11.3 (8.3 to 14.7) | 10.5 (7.7 to 13.3) |
| Dyspnea | 20.0 (19.3 to NA) | 20.8 (13.1 to NA) |
| Loss of Appetite | 8.3 (5.0 to 11.7) | 13.8 (9.6 to 16.1) |
| Insomnia | NA (17.3 to NA) | 15.2 (12.4 to NA) |
| Constipation | 9.2 (5.5 to 12.5) | 22.0 (15.9 to NA) |
| Diarrhea | 29.0 (17.2 to NA) | 16.5 (13.9 to 23.4) |
Blood samples were collected at indicated timepoints to determine ADA. Treatment-induced ADA was defined as ADA positive post-baseline and not detected at baseline (negative or missing). Treatment-boosted ADA was defined as a baseline positive ADA titer that was boosted to a 4-fold or higher-level following drug administration.
| Participants | T-DXd |
|---|---|
| Treatment-induced ADA | 22 |
| Treatment-boosted ADA | 0 |
TFST was defined as time from randomization to the start date of the first subsequent anti-cancer therapy after discontinuation of randomized treatment or death due to any cause.
Results for this outcome have not been posted.
TSST was defined as time from randomization to the start date of the second subsequent anti-cancer therapy after discontinuation of randomized treatment or death due to any cause.
Results for this outcome have not been posted.
Collected over From first dose of study drug (Day 1) up to PCD of 18 March 2024 (maximum of approximately 43.85 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T-DXd | 161/436 (36.9%) | 88/434 (20.3%) | 427/434 (98.4%) |
| Chemotherapy | 174/430 (40.5%) | 67/417 (16.1%) | 383/417 (91.8%) |
| Event | T-DXd | Chemotherapy |
|---|---|---|
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 8/434 | 0/417 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 8/434 | 0/417 |
| COVID-19Infections and infestations | 7/434 | 1/417 |
| CellulitisInfections and infestations | 1/434 | 5/417 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/434 | 5/417 |
| Febrile neutropeniaBlood and lymphatic system disorders | 5/434 | 2/417 |
| HypokalaemiaMetabolism and nutrition disorders | 5/434 | 1/417 |
| ColitisGastrointestinal disorders | 0/434 | 3/417 |
| DiarrhoeaGastrointestinal disorders | 1/434 | 3/417 |
| CholangitisHepatobiliary disorders | 0/434 | 3/417 |
| Event | T-DXd | Chemotherapy |
|---|---|---|
| NauseaGastrointestinal disorders | 301/434 | 126/417 |
| AlopeciaSkin and subcutaneous tissue disorders | 210/434 | 87/417 |
| AnaemiaBlood and lymphatic system disorders | 157/434 | 106/417 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 4/434 | 145/417 |
| DiarrhoeaGastrointestinal disorders | 148/434 | 112/417 |
| VomitingGastrointestinal disorders | 145/434 | 48/417 |
| ConstipationGastrointestinal disorders | 136/434 | 60/417 |
| FatigueGeneral disorders | 117/434 | 83/417 |
| Aspartate aminotransferase increasedInvestigations | 117/434 | 44/417 |
| Decreased appetiteMetabolism and nutrition disorders | 112/434 | 47/417 |
The Intent-to-treat (ITT) population included all randomized participants.
| Age, Continuous(years) | T-DXd | Chemotherapy | Total |
|---|---|---|---|
| Mean | 58.2 ± 11.46 | 58.2 ± 10.92 | 58.2 ± 11.19 |
| Sex: Female, Male(Participants) | T-DXd | Chemotherapy | Total |
|---|---|---|---|
| Female | 436 | 429 | 865 |
| Male | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | T-DXd | Chemotherapy | Total |
|---|---|---|---|
| Black or African American | 4 | 3 | 7 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 154 | 151 | 305 |
| White | 231 | 230 | 461 |
| Other | 7 | 12 | 19 |
| Not reported | 39 | 34 | 73 |
| Race/Ethnicity, Customized(Participants) | T-DXd | Chemotherapy | Total |
|---|---|---|---|
| Hispanic or Latino | 28 | 32 | 60 |
| Not Hispanic or Latino | 397 | 387 | 784 |
| Missing | 11 | 11 | 22 |
Showing the first 100 of 293 sites across 28 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jul 2020 to primary completion in Mar 2024, 43 months.
Results were first posted in Apr 2025, 1 year after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 43 months is close to that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab deruxtecan